Upload
dorit
View
33
Download
0
Embed Size (px)
DESCRIPTION
Various Strategies Used to Obtain Proteins for Crystallization and Biostructural Studies Dorothee Ambrosius, R. Engh, F. Hesse, M. Lanzendörfer, S. Palme, P. Rüger Roche Pharmaceutical Research, Penzberg. Protein Classes. extracellular proteins p lasma protein concentration: - PowerPoint PPT Presentation
Citation preview
P
harm
aceu
ticals
D. Ambrosius; slide 1 Proteine/RAMC-Presentation-9-01
Various Strategies Used to Obtain Proteins for
Crystallization and Biostructural Studies
Dorothee Ambrosius, R. Engh, F. Hesse,
M. Lanzendörfer, S. Palme, P. Rüger
Roche Pharmaceutical Research, Penzberg
P
harm
aceu
ticals
D. Ambrosius; slide 2 Proteine/RAMC-Presentation-9-01
Protein Classes
extracellular proteins
plasma protein concentration: 70 mg/ml
•transporter (albumin)•immuno-globulin•enzymes, enzyme-inhibitors•coagulation factors,
lipoproteins
protein characteristics/
stability •often monomeric proteins•contain disulfide bridges•protease resistant •stable fold
intracellular proteins
cytoplasma and organelles: 300-800 mg/ml
•multi-enzyme complexes•enzyme cascades•transcription complexes•focal adhesion/integrins•cytoskeleton, heat-shock
proteins
protein characteristics/stability
•often multimeric complexes•no disulfide bridges•very labile proteins; short
half-life •require stabilization:
interaction with other proteins
P
harm
aceu
ticals
D. Ambrosius; slide 3 Proteine/RAMC-Presentation-9-01
Protein Sources/Expression Systems
Expression system Advantages Examples Structure
E. coli soluble inclusion bodies
rapid cloning/ expression high yield isotope labeling possible
G-CSF; IBsPEX, IBsMIA, IBsIL-16, solubleMDM2, IBsPKA, soluble
NMRX-rayNMRNMRX-ray, NMRX-ray
Baculo/Insect cells
expression of active protein modifications
most Tyr kinases(RTK: IRK,c-met,SRC, LCK, etc.)Ser/Tyr kinasese.g. cdks, cAPK
X-ray/NMR
X-ray/NMR
RTS: E. coli parallel expression high throughput proteomics
see talk & posterJ . Stracke
P
harm
aceu
ticals
D. Ambrosius; slide 4 Proteine/RAMC-Presentation-9-01
Biological Function of Cytokines
G-CSFNeutrophils
Source: Herrmann/Lederle
P
harm
aceu
ticals
D. Ambrosius; slide 5 Proteine/RAMC-Presentation-9-01
Development Goals for Recombinant Human G-CSF
native sequence: without additional N-terminal Met
reduction of immunogenicity risk
potency: equal to Amgen´s Neupogen
low production cost: E. coli as host strain in vitro refolding
consistent quality: robust downstream scheme analytical methods
established
Hu-G-CSF: hematopoietic growth factor (174 aa)2 S-S bridges, one single Cys 17
Clinical use: patients with neutropenia: after chemotherapy improved haemotopoietic recovery
reduction of infectious risks
P
harm
aceu
ticals
D. Ambrosius; slide 6 Proteine/RAMC-Presentation-9-01
Genetic engineering of an economic downstream process
Strategy: Development of Recombinant Human G-CSF
Fusion Peptide
high level expression
improved refolding
efficient separation of cleaved and uncleaved protein
optimized cleavage site
Human G-CSFFusion Peptide
Protease
specific
efficient
recombinant
consistent quality
rhG-CSF
low production costs
without N-terminal Met
equal potency/efficiency
consistent quality
improved quality
P
harm
aceu
ticals
D. Ambrosius; slide 7 Proteine/RAMC-Presentation-9-01
Cleavage
-
++
++
+
+++
++
+++
Expression
(%)
100
30
100
100
25
10
100
Renaturation
(%)
10
20
20
50
90
80
80
Fusion Peptide
Met G-CSF
Met-Thr-Pro-Leu G-CSF
Met-Thr-Pro-Leu-His-His G-CSF
Met-Thr-Pro-Leu-Lys-Lys G-CSF
Met-Thr-Pro-Leu-Glu-Glu-Gly G-CSF
Met-Thr-Pro-Leu-Glu-Glu-Gly-Thr-Pro-Leu G-CSF
Met-Lys-Ala-Lys-Arg-Phe-Lys-Lys-His G-CSF
Cleavage Site (Pro-Arg-Pro-Pro)
Optimization of rhG-CSF Fusion Proteins
Source: EP 92102864.3 ; DE 4104580
P
harm
aceu
ticals
D. Ambrosius; slide 8 Proteine/RAMC-Presentation-9-01
Refolding Kinetics of rhG-CSF Fusion Protein
Solubilization6,0 M Gdn/HCl, pH 8.0 100 mM Tris,/HCl100 mM DTE 1 mM EDTATemperature: RTc= 20 mg/ml
Renaturation0,8 M Arginine/HCl100 mM Tris/HCl, pH 8.00.5 / 0.5 mM = GSH / GSSG10 mM EDTATemperature: RTProtein conc. 0.5 -1.0 mg /mlTime: 1- 2 hours
native
denat.
Source: EP 92102864.3 ; DE 4104580
Pellet SN
P
harm
aceu
ticals
D. Ambrosius; slide 9 Proteine/RAMC-Presentation-9-01
Role of p53 in cell cycle control:“guardian of the genome”
latent p53 active p53
activationaccumulation
h
stress factorsor oncogenic proteins mdm2
cell type level of p53 extent of DNA damage genetic background
cell cycle arrest: repair defective genes
apoptosis: kill harmful deregulated cells
negative feedback loop !!
P
harm
aceu
ticals
D. Ambrosius; slide 10 Proteine/RAMC-Presentation-9-01
Engineering of MDM2 for biostructural purposes
The MDM2 oncoprotein is a cellular inhibitor of the p53 tumor suppressor.
Goal: Improvement of biophysical properties of HDM2
(human MDM2) by “crystal engineering”
Known: XDM2 (Xenopus laevis MDM2): - better solubility, suitable for biostructural
investigations - wrong species and reduced binding affinity HDM2 (25-108): - high binding affinity to p53 peptide - prone to aggregation, not suitable for
biostructural studies
Strategy: use XDM2 as scaffold and humanize its p53-binding site
introduce point mutations in HDM2 to increase solubility
remove flexible ends at both sides of structured p53-binding
region
P
harm
aceu
ticals
D. Ambrosius; slide 11 Proteine/RAMC-Presentation-9-01
Figures taken from Kussie et al., Science 274 (1996) 948.
Structure of MDM2/p53-peptide complex
Resolution X-ray structures:
human MDM2/p53: 2.6 Å Xenopus MDM2/p53: 2.3 Å
p53
mdm2
17-29
26-108
P
harm
aceu
ticals
D. Ambrosius; slide 12 Proteine/RAMC-Presentation-9-01
MDM2 variants created by protein engineering
human MDM21 26 108 125 185 240 300 330 350 440 491
p53 binding
HDM2 (17-125) X-ray published
HDM2 (25-108) X-ray
HDM2 (25-108) mutants X-ray
XDM2 (13-119) X-ray published, NMR
XDM2 (13-119) LHI NMR, X-ray
XDM2 (21-105) LHI X-ray
I50L P92H
L95I
P
harm
aceu
ticals
D. Ambrosius; slide 13 Proteine/RAMC-Presentation-9-01
Step 15N-labeled non-labeled (LB)
(minimal medium)
Fermentation 10 L 10 L
E. coli (wet weight) 90 g 600 g
Inclusion bodies (w.w.) 3.5 g 85 g
IB total protein content 1.3 g 30 g
MDM2 (50-70% yield) 0.8 g 18 g
Renaturation (~25%) 0.2 g 4.5 g
MDM2 (Purification) 0.16 g 3.6 g
Final product 0.1 g 2.2 g
Human MDM2: Yields & Upscale
P
harm
aceu
ticals
D. Ambrosius; slide 14 Proteine/RAMC-Presentation-9-01
Crystals of hXDM/peptide
Some crystals comply withcorporate identity rules
hXDM2/p53 peptide
Patience might be rewarded
Conditions: 0.1 M MES pH 6.2, 4.0 M NaOOCH 3 days after micro seeding at 13 °C 4 months at 4 °C
hXDM2/phage-peptide
P
harm
aceu
ticals
D. Ambrosius; slide 15 Proteine/RAMC-Presentation-9-01
I: Ser/Thr-Kinase Families Subfamilies/StructuresIa: Non Receptor Ser/Thr-Kinase familiy
cAPK: cAMP dependent protein kinase PKA, PKB, PKCcdks: Cyclin dependent kinase cdk2, cdk4, cdk6
MAPK: Mitogen activated protein kinase Erk, Erk2, Jnk, p38(,,)
MLCK: Myosine light chain kinase Twitchin, TitinCK: Casein kinase Ck-1, Ck-2PhK: Phosphorylase kinase (tetramer: , , , ) PhK
CaMK: Calcium/calmodulin dependen kinase CaMK
Ib: Receptor Ser/Thr-Kinase familyTGF1-R Kinase TGF1-ßRII: Tyr-Kinase Families
Subfamilies/StructuresIIa: Non receptor Tyr-Kinase family
SRC-family SRC, c-SRC, CSK, HCK
LCK: humam lymphocyte kinase: LCK, c-Abl
IIb: Receptor Tyr-Kinase familyEGFR-family: EGFR, ErbB2-4InsR-family IRK, IGF1R, IRRPDGFR-, CSFR-, Met-, Ron-familiy, FGF1-R, VEGFR-KEphA1….EphB1, Trk A, B, C, etc.
Protein Kinase Families (incomplete list)
P
harm
aceu
ticals
D. Ambrosius; slide 16 Proteine/RAMC-Presentation-9-01
PKA: 2 Å X-ray StructureFurther details for crystallization see poster of Ch. Breitenlechner
P
harm
aceu
ticals
D. Ambrosius; slide 17 Proteine/RAMC-Presentation-9-01
PKA: cyclic AMP Dependent Protein KinaseExpression: E. coli, solubly expressed in phosphorylated,
active form 20-50 mg purified protein (10 l fermentation)
Purification: affinity chromatography with inhibitory peptide (PKI)
mimicking substrate binding Ref.: R. Engh & D. Bossemeyer, Adv. Enz. Reg.
41, 2001
Binding Affinity: 20 nM of inhibitory peptide (PKI)
Protein: MW: 35 kDa Ser/The kinase monomeric 2 domain (C- and N-lobe) protein
without additional regulatory domains (SH2, SH3, etc.) extended structured C- and N-Terminus, which
possibly stabilizes the overall kinase structure
Ideal model: Ser/Thr protein kinase inhibitor studies generation of other Ser/The kinase (e.g. PKB, Aurora) structures
P
harm
aceu
ticals
D. Ambrosius; slide 18 Proteine/RAMC-Presentation-9-01
Major Components of the Cell Cycle Machinery
mitogen induced progression through the cell cycle requires timely controlled activation of different cyclin-dependent kinases (CDKs)
cyclins (D, E, A, B), periodically expressed throughout the cycle, are the regulatory subunits of CDKs (activation)
members of the p16(INK4)- and p21(KIP)-protein family inhibit CDKs and CDK-cyclin complexes and arrest inappropriate cell cycle progression
G1
S
M
G2
Cell Cycle
G0
CDK2
cyclin A
CDC2
cyc. A/B CDK2
cyclin E
CDK4/6
cyclin D
CDC2
cyclin BMitosis
DNA Replication
INK4
Kip/Cip
Kip/Cip
P
harm
aceu
ticals
D. Ambrosius; slide 19 Proteine/RAMC-Presentation-9-01
Cyclin Dependent Kinases: CDK2 and CDK4/6
N. Pavletich, JMB 287, 821-828, 1999
P
harm
aceu
ticals
D. Ambrosius; slide 20 Proteine/RAMC-Presentation-9-01
Structural investigations of cdks (incomplete list) Structure Method Protein Expression system Referencep16p16
Folding studiesNMR
p16GST-p16
E. coli (IBs)E. coli (soluble)
Tang, 1999Byeon, 1998
p18
p18
NMR
X-ray: 1.95 Å
GST-p18
p18
E. coli (soluble)
BL21 (soluble)
Yuan, 1999
Venkataramani, 1998p19 NMR p19 E. coli (IBs) Baumgartner, 1999p19/cdk6, p16/cdk6
p19/cdk6
X-ray: 2.8 ÅX-ray: 3.4 Å
X-ray: 1.9 Å
cdk6GST-p19/p16
p19GST-cdk6
Baculo/insect cellsE. coli (soluble)
E. coli (soluble)Baculo/insect cells
Russo, 1998
Brotherton, 1998p18/cdk6/cycK X-ray: 2.9 Å GST-cycK
GST-p18cdk6
E. coli (soluble)E. coli (soluble)Baculo/insect cells
Jeffrey, 2000
cycA-cdk2cycA-ATPS-cdk2
X-ray: 2.3 ÅX-ray: 2.6 Å
cdk2cycA:
Baculo/insect cellsE.coli (soluble)
Jeffery, 1995Russo, 1996
cycA-ckk2-p27 X-ray: 2.3 Å p27 E. coli (soluble) Russo, 1996No strcuture GST-cdk4; cdk4 Baculo/insect cellscdk4 (mimic cdk2) X-ray cdk2, engineered
cdk4 pocketBaculo/insect cells Ikuta, 2001
P
harm
aceu
ticals
D. Ambrosius; slide 21 Proteine/RAMC-Presentation-9-01
Summary
Proteins show a tremendous diversity with respect to - biological function and cellular location- structure, conformation and stability
E. coli is a very attractive expression system with respect to time, yield, costs and production of isotope labeled proteins
Application of in vitro protein refolding is a powerful tool to generate native structured proteins and should be considered as alternative
The protein kinase family is regulated by multiple mechanism and show conformational diversity of catalytic cores; high degree of flexibility
- e.g. IRK(3P) and LCK (Tyr kinases) show structural homology to
cAPK and cdks (Ser/Thr kinases)
Until today, most kinases successfully applied for structural research are expressed as active P--enzyme in baculo/insect cells; exception PKA
P
harm
aceu
ticals
D. Ambrosius; slide 22 Proteine/RAMC-Presentation-9-01
Acknowledgement
PEX: S. Kanzler, H. Brandstetter (MPI)
MDM2: G. Saalfrank, Ch. Breitenlechner (MPI), U. Jacob (MPI)
IL-16: B. Essig , P. Mühlhahn (MPI), T. Holak (MPI)
MIA: G. Saalfrank, C. Hergersberg, R. Stoll (MPI), T. Holak (MPI)
cAPK: G. Achhammer, E. Liebig, Ch. Breitenlechner (MPI)
cdks: H. Hertenberger, J. Kluge, U. Jucknischke
G-CSF: S. Stammler, M. Leidenberger, U. Michaelis, T. Zink (MPI), T. Holak (MPI)